MERTK Inhibition Selectively Activates a DC–T Cell Axis to Provide Anti-Leukemia Immunity

Scientists probed anti-leukemia immune mechanisms and evaluated roles for TYRO3 and AXL in the leukemia microenvironment. Host Mertk knock-out or MERTK inhibitor MRX-2843 increased CD8α+ dendritic cells with enhanced antigen-presentation capacity in the leukemia microenvironment and inhibited leukemogenesis.